May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Ranibizumab (Lucentis) for PolypoidalChoroidal Vasculopathy
Author Affiliations & Notes
  • B. R. Baumrind
    Southeast Retina Center, Augusta, Georgia
  • H. Singh
    Southeast Retina Center, Augusta, Georgia
  • M. N. Lott
    Southeast Retina Center, Augusta, Georgia
  • J. Singh
    Southeast Retina Center, Augusta, Georgia
  • D. M. Marcus
    Southeast Retina Center, Augusta, Georgia
    Department of Ophthalmology, University of South Carolina School of Medicine, Columbia, South Carolina
  • Footnotes
    Commercial Relationships  B.R. Baumrind, None; H. Singh, Genentech, F; Eyetech, F; Regeneron, F; OPKO, F; Schlering-Plough, F; Eli-Lilly, F; Allergan, F; Alcon, F; DORC, F; Alimaera, F; M.N. Lott, None; J. Singh, None; D.M. Marcus, Genentech, F; Eyetech, F; Regeneron, F; OPKO, F; Schlering-Plough, F; Allergan, F; Alcon, F; DORC, F; Alimaera, F; Genentech, C; Eyetech, C.
  • Footnotes
    Support  Genentech Investigator initiated trial
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 299. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B. R. Baumrind, H. Singh, M. N. Lott, J. Singh, D. M. Marcus; Intravitreal Ranibizumab (Lucentis) for PolypoidalChoroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2008;49(13):299. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine safety and efficacy of intravitreal ranibizumab for polypoidal choroidal vasculopathy (PCV).

Methods: : Phase I/II safety study, open-label, single-center, non-randomized, uncontrolled, consecutive case-series. Prospective, random sample of 13 consecutive adults, age >35 years, with exudative, active PCV defined as CNV with occult characteristics on fluorescein angiography with saccular dilations and polypoidal interconnecting vascular channels on indocyanine green angiography and/or fluorescein angiography. Eyes received 3 consecutive monthly intravitreal ranibizumab injections (0.5mg or 0.3 mg/0.05 cc) followed by monthly evaluations with options of intravitreal ranibizumab or other therapies at the discretion of the investigator. Baseline and monthly evaluations included medical history, blood pressure, physical exam, ETDRS chart best-corrected visual acuity, intraocular pressure measurement, and complete ophthalmologic exam, fluorescein/ICG angiography, fundus photography, and optical coherence tomography (OCT).

Results: : Thirteen subjects were enrolled and included 11 African Americans (9 female, 2 male) and 2 Caucasians (both male) with 9.7 month average follow-up (range 1-17 months). Average baseline visual acuity (VA) and OCT central subfield thickness was 20/154 (range 20/25-20/500) and 334 microns (range 122-607), respectively. After the first two ranizibumab injections, average VA was 20/141 (range20/25-20/400) and average OCT thickness decreased to 227 (range 132-383). At last follow-up visit, average VA average was 20/108 (range 20-400) and average OCT thickness 255 (range 132-438). At the last followup visit, 6, 3, and 4 eyes demonstrated improved, unchanged, and worsened VA, respectively. Eight of 9 eyes with baseline OCT thickness >200 um demonstrated decreased thickness after ranibizumab. Complications included macular hole development in 1 patient with vitreous and subretinal hemorrhage present at enrollment and cataract progression requiring cataract extraction in 1 patient.

Conclusions: : Intravitreal ranibizumab is safe and results in decreased retinal thickness and improved visual acuity in a significant proportion of eyes with PCV.

Keywords: choroid: neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.